Income Statement Presentation 2023
Pharma portfolio rejuvenation ongoing
16 blockbusters at the end of 2022, compared to 8 in 2015
TECENTRIQ™
atezolizumab
VENCLEXTA
venetoclax tablets
100
LUXTURNA
voretigene neparvovec-rzyl
subretinal injection
xofluza
(balaavir marbeniables
HEMLIBRA.
emicizumab-kxwh
50
SALECENSA™
alectinib
capsules
OCREVUS
ocrelizumab
×COTELLIC
POLIVY
polatuzumab vedotin
ENSPRYNG
ROZLYTREK
PHESGO
pertuzumab trastuzumabund
SUBCUTANE BUSINE
CHFM
20,000
SuSvim o™
Evrysdi.
ranibizumab injection
15,000
risdiplam
GAVRETO
praisetino
24%
VABYSMO
Lunsumic
10,000
RONAPREVE
casirivimab and indevimab
mosunetuzumab
16%
2016 2017
2018 | 2019 2020 2021 2022
2023
Expected NME
launches:**
⚫ glofitamab
SRP-9001
crovalimab
5,000
35%
Roche
% of Pharma Sales*
44%
0
FY 2019
FY 2020
Cotellic
Hemlibra
Alecensa
Xofluza
FY 2021
Tecentriq
FY 2022
Ocrevus
Polivy
Rozlytrek
Phesgo
Enspryng
Evrysdi
Gavreto
Ronapreve
Susvimo
Vabysmo
Lunsumio
* Venclexta sales booked by AbbVie and therefore not included, ** SRP-9001: Accelerated US-filing by partner company Sarepta; crovalimab: First filing in China
11View entire presentation